Compare ASTH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | CAPR |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | ASTH | CAPR |
|---|---|---|
| Price | $22.01 | $24.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $40.78 | ★ $41.38 |
| AVG Volume (30 Days) | 553.4K | ★ 1.2M |
| Earning Date | 03-02-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,896,452,000.00 | $11,130,509.00 |
| Revenue This Year | $58.46 | N/A |
| Revenue Next Year | $25.59 | $16,329.74 |
| P/E Ratio | $108.92 | ★ N/A |
| Revenue Growth | ★ 68.17 | N/A |
| 52 Week Low | $20.12 | $4.30 |
| 52 Week High | $39.97 | $40.37 |
| Indicator | ASTH | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 53.25 |
| Support Level | $20.92 | $21.75 |
| Resistance Level | $22.97 | $24.93 |
| Average True Range (ATR) | 1.53 | 1.32 |
| MACD | -0.59 | -0.16 |
| Stochastic Oscillator | 20.79 | 73.49 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.